Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBIT (2016 - 2025)

Historic EBIT for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.3 million.

  • Enanta Pharmaceuticals' EBIT rose 5220.24% to -$11.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$73.1 million, marking a year-over-year increase of 3379.22%. This contributed to the annual value of -$85.3 million for FY2025, which is 2986.42% up from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' EBIT stood at -$11.3 million, which was up 5220.24% from -$18.4 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year EBIT high stood at -$11.3 million for Q4 2025, and its period low was -$39.5 million during Q1 2023.
  • Its 5-year average for EBIT is -$28.8 million, with a median of -$30.2 million in 2021.
  • Per our database at Business Quant, Enanta Pharmaceuticals' EBIT plummeted by 15010.53% in 2021 and then soared by 5220.24% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' EBIT stood at -$30.4 million in 2021, then rose by 1.3% to -$30.0 million in 2022, then dropped by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then skyrocketed by 52.2% to -$11.3 million in 2025.
  • Its EBIT stands at -$11.3 million for Q4 2025, versus -$18.4 million for Q3 2025 and -$18.9 million for Q2 2025.